{"id":"W4414380597","doi":"10.1016/j.ygyno.2025.09.001","title":"Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907)","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Gilead UK and Ireland Corporate Contributions; Gilead Sciences","keywords":"Cervical cancer; Phases of clinical research; Phase (matter); Cancer; Cervical carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000594146,0.0005824405,0.0009909789,0.0003265896,0.0002616429,0.0006086604,0.000396842,0.0004977927,0.00235219],"category_scores_gemma":[0.0005833663,0.0002359643,0.0008720476,0.0007429149,0.0003364581,0.0003717393,0.0002687415,0.0008667091,0.0004054632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007726324,"about_ca_system_score_gemma":0.00127641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006302456,"about_ca_topic_score_gemma":0.02501058,"domain_scores_codex":[0.999815,0.0000601441,0.00001043789,0.00003381096,0.00003186392,0.00004868616],"domain_scores_gemma":[0.9998329,0.0000270707,0.00004813812,0.00001401329,0.00002002341,0.00005787862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3767248,0.008675166,0.2225565,0.002419635,0.01063709,0.0007340686,0.0006877117,0.003376197,0.03186789,0.000721788,0.02064259,0.3209566],"study_design_scores_gemma":[0.2460648,0.06407773,0.6414322,0.0003047076,0.01446584,0.000742032,0.0007168762,0.004087215,0.003866525,0.001037341,0.02306956,0.0001351959],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990798,0.004553165,0.0001098754,0.0004777067,0.00006944643,0.000245835,0.001831266,0.00003682214,0.00187782],"genre_scores_gemma":[0.989995,0.003250174,0.000279581,0.0007253868,0.0000920121,0.0001900764,0.003653553,0.00001397496,0.001800191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006302456,"threshold_uncertainty_score":0.01253152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0235962346395399,"score_gpt":0.3596982165339163,"score_spread":0.3361019818943764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}